Two other trials with nAChR agonists were less convincing; efficacy of ispronicline (TC-1734 or AZD-3480) a selective agonist of α4β2 nAChR and α2β2 nAChR (Gatto et al., 2004) was investigated in a large Phase IIb dose-finding study on mild to moderate AD patients (MMSE score: 12–26). The gene discussed is CHRNA4; the disease is Alzheimer disease.